Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Avanos Medical (AVNS) FCF Margin (2016 - 2025)

Avanos Medical's FCF Margin history spans 11 years, with the latest figure at 11.74% for Q3 2024.

  • For Q3 2024, FCF Margin fell 297.0% year-over-year to 11.74%; the TTM value through Dec 2024 reached 16.31%, up 1414.0%, while the annual FY2023 figure was 2.17%, 830.0% down from the prior year.
  • FCF Margin for Q3 2024 was 11.74% at Avanos Medical, down from 12.75% in the prior quarter.
  • Across five years, FCF Margin topped out at 132.4% in Q4 2021 and bottomed at 7.28% in Q1 2024.
  • The 5-year median for FCF Margin is 3.92% (2023), against an average of 10.53%.
  • The largest annual shift saw FCF Margin surged 13456bps in 2021 before it crashed -11233bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 2.16% in 2020, then surged by 6224bps to 132.4% in 2021, then tumbled by -85bps to 20.07% in 2022, then plummeted by -80bps to 3.92% in 2023, then surged by 199bps to 11.74% in 2024.
  • Per Business Quant, the three most recent readings for AVNS's FCF Margin are 11.74% (Q3 2024), 12.75% (Q2 2024), and 7.28% (Q1 2024).